STOCK TITAN

Alnylam (ALNY) director sells 3,830 shares after expiring option exercise

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ALNYLAM PHARMACEUTICALS, INC. director David E I Pyott exercised a stock option for 3,830 shares of common stock at a conversion price of $70.20 per share and sold the same 3,830 shares in open-market transactions on June 1, 2026. The reported sales occurred at weighted average prices around $297.71–$302.65 per share under a pre-arranged Rule 10b5-1(c) trading plan, and the options were due to expire on June 3, 2026. Following these transactions, he holds 1,582 shares of common stock directly and 27,900 shares indirectly through the David E I Pyott Trust, of which he is trustee.

Positive

  • None.

Negative

  • None.
Insider PYOTT DAVID E I
Role null
Sold 3,830 shs ($1.15M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 3,830 $0.00 --
Exercise Common Stock 3,830 $0.00 --
Sale Common Stock 921 $297.71 $274K
Sale Common Stock 1,175 $298.91 $351K
Sale Common Stock 1,222 $299.87 $366K
Sale Common Stock 495 $300.72 $149K
Sale Common Stock 17 $302.65 $5K
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct, null); Common Stock — 5,412 shares (Direct, null); Common Stock — 27,900 shares (Indirect, by Trust)
Footnotes (1)
  1. The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee. This stock option was fully vested and exercisable as of June 3, 2017.
Options exercised 3,830 shares Stock option for common stock exercised on June 1, 2026
Exercise price $70.20/share Conversion or exercise price of stock option exercised
Shares sold 3,830 shares Total common shares sold in open-market transactions
Sale price range $297.31–$302.65 Weighted average sale prices across multiple transactions
Direct holdings after 1,582 shares Common stock directly owned after transactions
Trust holdings 27,900 shares Common stock held by the David E I Pyott Trust
Option expiration June 3, 2026 Expiration date of the exercised stock option
Option fully vested June 3, 2017 Date option became fully vested and exercisable
Rule 10b5-1(c) trading plan financial
"The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person"
A Rule 10b5-1(c) trading plan is a legally defined, pre-set schedule that lets company insiders automatically buy or sell stock at specified times or under set formulas when they are not in possession of undisclosed, sensitive information. Think of it like an automatic payment plan for trades: because the instructions are written in advance, trades under the plan help protect insiders from allegations of trading on secret information and give investors clearer expectations about when insiders will transact, which can affect liquidity and perceived transparency.
weighted average sales price financial
"The price reported represents the weighted average sales price of shares sold in multiple transactions"
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
fully vested and exercisable financial
"This stock option was fully vested and exercisable as of June 3, 2017"
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PYOTT DAVID E I

(Last)(First)(Middle)
675 WEST KENDALL STREET

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/01/2026M(1)3,830A$05,412D
Common Stock06/01/2026S(1)921D$297.71(2)4,491D
Common Stock06/01/2026S(1)1,175D$298.91(3)3,316D
Common Stock06/01/2026S(1)1,222D$299.87(4)2,094D
Common Stock06/01/2026S(1)495D$300.72(5)1,599D
Common Stock06/01/2026S(1)17D$302.651,582D
Common Stock27,900Iby Trust(6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$70.206/01/2026M(1)3,83006/03/2017(7)06/03/2026Common Stock3,830$00D
Explanation of Responses:
1. The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.
2. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
5. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
6. The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee.
7. This stock option was fully vested and exercisable as of June 3, 2017.
Brett Budzinski, Attorney-in-Fact For: David E.I. Pyott06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ALNY director David E I Pyott report?

David E I Pyott reported exercising options for 3,830 Alnylam common shares and selling the same 3,830 shares in open-market transactions on June 1, 2026. The filing shows both the derivative option exercise and subsequent common stock sales.

At what prices did David E I Pyott sell ALNY shares?

Pyott’s Alnylam share sales used weighted average prices between about $297.31 and $302.65 per share. Footnotes explain these averages cover multiple trades within narrow price ranges and that detailed breakdowns are available upon request from the company or SEC staff.

What stock option did David E I Pyott exercise in this ALNY Form 4?

He exercised a stock option for 3,830 Alnylam common shares with a conversion or exercise price of $70.20 per share. The option was fully vested and exercisable since June 3, 2017 and was scheduled to expire on June 3, 2026, according to the filing.

How many ALNY shares does David E I Pyott hold after these transactions?

After the reported transactions, Pyott holds 1,582 Alnylam common shares directly and 27,900 shares indirectly. The indirect holdings are owned by the David E I Pyott Trust, where he serves as trustee, as disclosed in the ownership footnote.

Was the ALNY insider sale by David E I Pyott under a Rule 10b5-1 plan?

Yes. The filing states all reported transactions were made under a Rule 10b5-1(c) trading plan adopted on November 12, 2025. Such plans pre-schedule trades, which can make the timing less indicative of the insider’s view of the stock.

Did David E I Pyott retain any ALNY stock options after this exercise?

The Form 4 shows a derivative transaction in which a 3,830-share stock option was exercised, leaving zero shares remaining under that option. The derivative summary section is otherwise empty, indicating no additional derivative positions are reported in this filing.